NIPT test available for every pregnant woman
From April 1st 2017, the NIPT test will be available for every pregnant women. Minister Edith Schippers (Health, Welfare and Sport) announced that 26 million euro is available for the NIPT.
The NIPT test is a blood test for pregnant women to determine whether the unborn child has an extra chromosome 21 (Down’s syndrome), 13 (Pautau syndrome) or 18 (Edwards syndrome). For pregnant women invasive tests are now no longer needed and the chances on miscarriage are thus reduced.
The NIPT consortium, in which the Dutch UMC’s among others cooperate with professional organizations NVOG, VKGN and VKGL, performed the TRIDENT study (Trial by Dutch laboratories for Evaluation of Non-invasive Prenatal Testing). EMGO+ researchers Dr Lidewij Henneman, Prof. Martina Cornel, and Rachèl van Schendel (all three of the VUmc Department of Clinical Genetics, section Community Genetics) were involved in the TRIDENT study, that made clear how the provision of the NIPT test in the Netherlands should be organized and carried out.
On May 19th at the EMGO+ Annual Meeting, Lidewij Henneman was awarded the Societal Impact Award 2016 (a prize to the product with the highest societal impact) for the license application for the implementation of the non-invasive prenatal test (NIPT) in the Netherlands.
Back to the newsletter